The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC
Program Goals
Discussion Overview
Overall Landscape Today: Still Rapidly Evolving
Where Are We in 2015?
Docetaxel in Hormone Treatment-Naive Disease
The Expanding Role of Abiraterone and Enzalutamide
How to Choose Between Abiraterone and Enzalutamide?
St Gallen Advanced Prostate Cancer Consensus Conference (APCCC 2015)
A Major Metabolite of Abiraterone in Humans Is a Potent AR Antagonist
Other Clinical Considerations for Abiraterone and Enzalutamide
Steroid Switch Results in Durable Responses
Other Therapeutic Options for mCRPC
Local Recurrence Symptoms Becoming an Increasing Problem
State of the Art Treatment for mCRPC: Recommendations
Clinical Genomics of Advanced Prostate Cancer: AR Pathway Aberrations
PI3K Pathway Aberrations in mCRPC
What Is the Meaning of All of This? CRPC Remains AR-Driven
What About PI3K/AKT Signaling? We May Also Need to Block AKT
DNA Repair Aberrations
Olaparib in mCRPC: Phase 2 TOPARP Trial
Olaparib in mCRPC: Results
Conclusions
Abbreviations
Abbreviations (cont)